SEC Form 4 · accession 0001171843-18-001659
Anika Therapeutics, Inc. · ANIK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward S. Ahn
Officer — Chief Tech & Strategy Officer
Period of report
Mar 2, 2018
Accepted (ET)
Mar 2, 2018 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000898437
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1,F3 | $50.13 | Mar 2, 2018 | A | 7,788 | A | — | Jan 27, 2027 | Common Stock | 7,788 | 7,788 | D |
Explanation of responses
- F1The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3.
- F2On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3.
- F3The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020.